edelfosine has been researched along with Breast Cancer in 15 studies
edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18-OCH3), an alkyl lysophospholipid derivative, on the binding of epidermal growth factor (EGF) to human breast cancer cell lines (MCF-7, ZR-75-1, and BT-20), the human epidermoid cancer cell line (A431), and the rat fibroblast cell line (NIH3T3) were investigated." | 7.67 | Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. ( Kosano, H; Takatani, O, 1988) |
| "Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units." | 5.39 | Efficacy of edelfosine lipid nanoparticles in breast cancer cells. ( Aznar, MÁ; Blanco-Prieto, MJ; Estella-Hermoso de Mendoza, A; Lasa-Saracíbar, B, 2013) |
| "High-dose chemotherapy combined with autologous stem cell support has improved response rates in high-risk and metastatic breast cancer, but has failed to improve long-term survival." | 5.31 | Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. ( Anderson, GS; Miyagi, K; Sampson, RW; Sieber, F, 2002) |
| "Using cell migration-proliferation assays, patch clamp, spectrofluorimetry and ¹²⁵I-Apamin binding experiments, we studied the effects of edelfosine on the migration of breast cancer MDA-MB-435s cells, mediated by the small conductance Ca²(+) -activated K(+) channel, SK3/K(Ca)2." | 3.77 | The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. ( Besson, P; Bougnoux, P; Chantome, A; Girault, A; Joulin, V; Jourdan, ML; LeGuennec, JY; Potier, M; Roger, S; Vandier, C, 2011) |
| "The effects of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18-OCH3), an alkyl lysophospholipid derivative, on the binding of epidermal growth factor (EGF) to human breast cancer cell lines (MCF-7, ZR-75-1, and BT-20), the human epidermoid cancer cell line (A431), and the rat fibroblast cell line (NIH3T3) were investigated." | 3.67 | Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. ( Kosano, H; Takatani, O, 1988) |
| "Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units." | 1.39 | Efficacy of edelfosine lipid nanoparticles in breast cancer cells. ( Aznar, MÁ; Blanco-Prieto, MJ; Estella-Hermoso de Mendoza, A; Lasa-Saracíbar, B, 2013) |
| "Edelfosine is an inhibitor of SK3 channel mediated cell migration." | 1.37 | New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. ( Bougnoux, P; Chantome, A; Corbel, B; Couthon-Gourvès, H; Girault, A; Haelters, JP; Jaffrès, PA; Joulin, V; Marionneau-Lambot, S; Oullier, T; Pinault, M; Potier-Cartereau, M; Simon, G; Vandier, C, 2011) |
| "When MCF-7 human breast cancer cells were exposed to an aqueous solution of *NO delivered as a bolus 30 min prior to doxorubicin, the cytotoxic effect as measured in a clonogenic assay was increased (doxorubicin alone, 40% survival, doxorubicin plus *NO, 5% survival)." | 1.32 | Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. ( Buettner, GR; Burns, CP; Chu, Y; Evig, CB; Kelley, EE; Weydert, CJ, 2004) |
| "High-dose chemotherapy combined with autologous stem cell support has improved response rates in high-risk and metastatic breast cancer, but has failed to improve long-term survival." | 1.31 | Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. ( Anderson, GS; Miyagi, K; Sampson, RW; Sieber, F, 2002) |
| "The MCF-7/6 human breast cancer cells were used as negative control since their E-cadherin/catenin complex is functional in cells grown on solid substrate but not in suspension." | 1.31 | Alkyl-lysophospholipid 1-O-octadecyl-2-O-methyl- glycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro. ( Bruyneel, EA; Delannoy, P; Goeman, JL; Hilkens, J; Huet, G; Krzewinski-Recchi, MA; Mareel, MM; Oomen, LC; Philippé, J; Steelant, WF; Van der Eycken, J, 2001) |
| "with MDA-MB 231 human breast carcinoma cells." | 1.30 | Effects of iron supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in nude mice consuming a fish oil diet. ( Barnes, CJ; Cameron, IL; Hardman, WE; Knight, CW, 1997) |
| "Two MCF-7 human breast cancer cell variants were studied: MCF-7/AZ cells showed a spontaneous cell-cell adhesion in the fast and slow aggregation assay." | 1.30 | Sialylation of E-cadherin does not change the spontaneous or ET-18-OMe-mediated aggregation of MCF-7 human breast cancer cells. ( Boilly-Marer, Y; Bruyneel, EA; Delannoy, P; Mareel, MM; Noë, VT; Recchi, MA; Steelant, WF; Verbert, A, 1999) |
| "Four cell lines from human breast cancer (HTB 19, HTB 133, IZB B, and MCF 7M) were investigated for in vitro growth before and after incubation with the ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) for 4 h and at increasing concentrations (25, 50, 75, and 100 micrograms/ml), as well as with and without cryopreservation." | 1.29 | Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. ( Berdel, WE; Dietzfelbinger, HF; Hanauske, AR; Kühn, D; Rastetter, JW; Zafferani, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aznar, MÁ | 1 |
| Lasa-Saracíbar, B | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Blanco-Prieto, MJ | 1 |
| Potier, M | 1 |
| Chantome, A | 2 |
| Joulin, V | 2 |
| Girault, A | 2 |
| Roger, S | 1 |
| Besson, P | 2 |
| Jourdan, ML | 1 |
| LeGuennec, JY | 1 |
| Bougnoux, P | 3 |
| Vandier, C | 2 |
| Haelters, JP | 1 |
| Potier-Cartereau, M | 1 |
| Pinault, M | 1 |
| Marionneau-Lambot, S | 1 |
| Oullier, T | 1 |
| Simon, G | 1 |
| Couthon-Gourvès, H | 1 |
| Jaffrès, PA | 1 |
| Corbel, B | 1 |
| Anderson, GS | 1 |
| Miyagi, K | 1 |
| Sampson, RW | 1 |
| Sieber, F | 1 |
| Evig, CB | 1 |
| Kelley, EE | 1 |
| Weydert, CJ | 1 |
| Chu, Y | 1 |
| Buettner, GR | 1 |
| Burns, CP | 1 |
| Van Slambrouck, S | 1 |
| Steelant, WF | 3 |
| Dietzfelbinger, HF | 1 |
| Kühn, D | 1 |
| Zafferani, M | 1 |
| Hanauske, AR | 1 |
| Rastetter, JW | 1 |
| Berdel, WE | 1 |
| Goré, J | 1 |
| Vincent, E | 1 |
| Hoinard, C | 1 |
| Marino-Albernas, JR | 1 |
| Bittman, R | 1 |
| Peters, A | 1 |
| Mayhew, E | 1 |
| Hardman, WE | 1 |
| Barnes, CJ | 1 |
| Knight, CW | 1 |
| Cameron, IL | 1 |
| Recchi, MA | 1 |
| Noë, VT | 1 |
| Boilly-Marer, Y | 1 |
| Bruyneel, EA | 2 |
| Verbert, A | 1 |
| Mareel, MM | 2 |
| Delannoy, P | 2 |
| Samadder, P | 1 |
| Arthur, G | 1 |
| Goeman, JL | 1 |
| Philippé, J | 1 |
| Oomen, LC | 1 |
| Hilkens, J | 1 |
| Krzewinski-Recchi, MA | 1 |
| Huet, G | 1 |
| Van der Eycken, J | 1 |
| Kosano, H | 2 |
| Yasutomo, Y | 1 |
| Kugai, N | 1 |
| Nagata, N | 1 |
| Inagaki, H | 1 |
| Tanaka, S | 1 |
| Takatani, O | 2 |
15 other studies available for edelfosine and Breast Cancer
| Article | Year |
|---|---|
Efficacy of edelfosine lipid nanoparticles in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Survival; Diglycerides; Female; | 2013 |
The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine.
Topics: Antineoplastic Agents; Apamin; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Membrane; Cell Migr | 2011 |
New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Dose-Response Rel | 2011 |
Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients.
Topics: Animals; Antigens, CD; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2002 |
Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts.
Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Line; Cell Li | 2004 |
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesi | 2007 |
Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation.
Topics: Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cryoprese | 1993 |
Inhibition of Na+/H+ exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line.
Topics: Antineoplastic Agents; Breast Neoplasms; Buffers; Humans; Hydrogen-Ion Concentration; Kinetics; Phos | 1996 |
Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Female; Glycosides; Huma | 1996 |
Effects of iron supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in nude mice consuming a fish oil diet.
Topics: Animals; Breast Neoplasms; Dietary Fats, Unsaturated; Eicosanoids; Fish Oils; Growth Inhibitors; Hum | 1997 |
Sialylation of E-cadherin does not change the spontaneous or ET-18-OMe-mediated aggregation of MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cadherins; Cell Aggregation; Cell Survival; Female; Glycopr | 1999 |
Decreased sensitivity to 1-O-octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes.
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Division; Cell Membrane; Clone C | 1999 |
Alkyl-lysophospholipid 1-O-octadecyl-2-O-methyl- glycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro.
Topics: Antibodies, Monoclonal; beta Catenin; Biotinylation; Blotting, Northern; Blotting, Western; Breast N | 2001 |
Inhibition of estradiol uptake and transforming growth factor alpha secretion in human breast cancer cell line MCF-7 by an alkyl-lysophospholipid.
Topics: Antineoplastic Agents; Breast Neoplasms; Estradiol; Humans; Neoplasms, Hormone-Dependent; Phospholip | 1990 |
Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid.
Topics: Antineoplastic Agents; Breast Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Ph | 1988 |